eCTD Publishing Services — Submission-Perfect Electronic Dossiers
Sub-headline: Expert eCTD publishing services and regulatory publishing for pharmaceutical and medical device submissions to FDA, EMA, MHRA, and global health authorities. RABT Global delivers technically validated, submission-ready eCTD packages.
Get expert eCTD submission services and lifecycle eCTD management — delivered by RABT Global’s specialist regulatory publishing team.
eCTD publishing services are a technically demanding but often underestimated component of the regulatory submission process. An incorrectly structured or technically invalid eCTD submission will be rejected by health authorities — potentially triggering lengthy delays and re-submission cycles. As eCTD becomes mandatory across an increasing number of global markets, the quality of your electronic submission publishing services can make or break your submission timeline.
At RABT Global, our eCTD publishing services are delivered by a specialist team of regulatory publishers with deep expertise in FDA eCTD submission services, EMA eCTD requirements, and global eCTD publishing solutions. We use leading eCTD authoring and publishing platforms to produce technically compliant, health authority-ready eCTD packages for every submission type.
Our regulatory publishing services are fully integrated with RABT Global’s regulatory affairs and medical writing teams — ensuring seamless document flow from authoring through to publishing and submission. Whether you need support for a single submission or ongoing lifecycle eCTD management for a large pharmaceutical portfolio, our eCTD consulting services deliver the speed, quality, and technical precision your submissions require.
Our eCTD Publishing & Regulatory Publishing Services
KEY SERVICES — ECTD PUBLISHING
Initial eCTD Application Publishing
complete eCTD compilation and publishing for NDA, ANDA, MAA, BLA, and equivalent applications
FDA eCTD Submission Services
US eCTD submissions to FDA via ESG gateway, with pre-submission technical validation
EMA eCTD Publishing
EU eCTD submissions via eSubmission gateway, NeeS, and EMA-specific technical requirements
Lifecycle eCTD Management
ongoing eCTD sequence management for variations, supplements, and post-approval changes
eCTD Technical Validation
pre-submission validation against FDA and EMA technical specifications and validation criteria
Regulatory Document Publishing
preparation and formatting of all CTD documents to applicable electronic submission standards
Conversion & Migration Services
conversion of legacy paper and non-eCTD submissions to eCTD format
Global eCTD Publishing Solutions
eCTD publishing for Health Canada, PMDA Japan, and other eCTD-adopting markets
What are eCTD Publishing Services?
eCTD (electronic Common Technical Document) publishing services involve the technical compilation, structuring, and formatting of pharmaceutical regulatory submission documents into the eCTD electronic submission format required by major health authorities including the FDA, EMA, MHRA, and Health Canada. eCTD publishing services ensure that submission packages meet all technical specifications, pass electronic validation, and are ready for health authority submission and review.
eCTD Publishing Services — FAQs
A: The electronic Common Technical Document (eCTD) is the electronic format for regulatory submissions to health authorities including the FDA (mandatory for NDAs/BLAs/ANDAs since 2017), EMA, and MHRA. eCTD provides a structured, navigable electronic dossier that facilitates health authority review. Non-compliant eCTD submissions will be rejected by technical validation checks before reaching reviewers.
A: RABT Global’s eCTD publishing team uses industry-leading eCTD authoring and publishing platforms, validated against FDA and EMA technical specifications. We select the optimal publishing tool based on the target agency and submission type to ensure maximum technical compliance.
A: Timeline depends on dossier size and complexity. For standard applications, RABT Global’s regulatory publishing services typically deliver a validated eCTD package within 3–7 business days from document receipt. Rush timelines are available for urgent submissions — contact our team to discuss your specific timeline requirements.
A: Yes. Our lifecycle eCTD management service covers all post-approval sequences — including Type I/II variations (EU), Prior Approval Supplements (FDA), Annual Reports, PSUR submissions, and other lifecycle eCTD sequences. We maintain your complete eCTD submission history as part of our ongoing regulatory publishing services.
Get Submission-Perfect eCTD Publishing from RABT Global
Expert eCTD publishing services and regulatory document publishing — technically validated, health authority-ready, and delivered on your timeline.